Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Circulating tumor DNA (ctDNA) informs clinical practice in patients with recurrent/metastatic gastroesophageal cancers.
Authors
Rutika Mehta
H. Lee Moffitt Cancer Center, Tampa, FL;
Rutika Mehta , Samuel Rivero-Hinojosa , Farshid Dayyani , Joseph Chao , Jesus Izaguirre Carbonell , Jenifer Ferguson , Bushra Shariff , Vasily N. Aushev , Griffin Budde , Shruti Sharma , Meenakshi Malhotra , Adham A Jurdi , Minetta C. Liu , Samuel J Klempner , Brandon Huffman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Translational Research
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 427)
DOI
10.1200/JCO.2023.41.4_suppl.427
Abstract #
427
Poster Bd #
J11
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Association of positive ctDNA-based minimal residual disease assays during surveillance and undiagnosed concomitant radiographic recurrences in colorectal cancer (CRC): Results from the MD Anderson INTERCEPT program.
First Author: Arvind Dasari
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A single-center comparative surveillance strategies of ctDNA (Signatera), imaging, and CEA in the surveillance of resected colorectal cancer.
First Author: Jaideep Singh Sandhu
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Minimal residual disease assessment in colorectal cancer (MiRDA-C).
First Author: Arvind Dasari
Poster
2024 ASCO Gastrointestinal Cancers Symposium
INTERCEPT Program of circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) in colorectal cancer (CRC): Results from a prospective clinical cohort.
First Author: Giulia Maddalena